These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 14034203)

  • 21. [Coronary dilator action of 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d)pyrimidine: experimental coronary radiographic findings].
    ROVELLI F; BARBACCIA F; DISTANTE S; DONATELLI R
    Atti Soc Ital Cardiol; 1962; 22(2)():Comunicazioni 72-4. PubMed ID: 13982780
    [No Abstract]   [Full Text] [Related]  

  • 22. Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms.
    Bhatheja R; Francis GS; Pothier CE; Lauer MS
    Am J Cardiol; 2005 May; 95(10):1159-64. PubMed ID: 15877986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study.
    Sanada S; Asanuma H; Koretsune Y; Watanabe K; Nanto S; Awata N; Hoki N; Fukunami M; Kitakaze M; Hori M
    Hypertens Res; 2007 Oct; 30(10):913-9. PubMed ID: 18049022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation of Trp29 of human equilibrative nucleoside transporter 1 alters affinity for coronary vasodilator drugs and nucleoside selectivity.
    Paproski RJ; Visser F; Zhang J; Tackaberry T; Damaraju V; Baldwin SA; Young JD; Cass CE
    Biochem J; 2008 Sep; 414(2):291-300. PubMed ID: 18462193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and therapeutic implications of dipyridamole stress cardiovascular magnetic resonance on the basis of the ischaemic cascade.
    Bodi V; Sanchis J; Lopez-Lereu MP; Nunez J; Mainar L; Monmeneu JV; Ruiz V; Rumiz E; Husser O; Moratal D; Millet J; Chorro FJ; Llacer A
    Heart; 2009 Jan; 95(1):49-55. PubMed ID: 18381373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ischaemia and outcome with normal coronary arteries.
    Marwick TH
    Eur Heart J; 2005 Oct; 26(20):2077-8. PubMed ID: 16141255
    [No Abstract]   [Full Text] [Related]  

  • 27. Treadmill exercise produces larger perfusion defects than dipyridamole stress N-13 ammonia positron emission tomography.
    Chow BJ; Beanlands RS; Lee A; DaSilva JN; deKemp RA; Alkahtani A; Ruddy TD
    J Am Coll Cardiol; 2006 Jan; 47(2):411-6. PubMed ID: 16412870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [On the biological evaluation of coronary dilator agents].
    KHADZHAI IaI; CHERKASOVA IN
    Farmakol Toksikol; 1962; 25():573-8. PubMed ID: 14032230
    [No Abstract]   [Full Text] [Related]  

  • 29. [On several derivatives of 2- and 4-(beta-phenlpropionyl)-phenoxyacetic acids with presumed coronary-dilator action].
    BRAMANTI G; DI PACO GF
    Boll Chim Farm; 1962 Oct; 101():796-808. PubMed ID: 14014910
    [No Abstract]   [Full Text] [Related]  

  • 30. [Therapeutic experiences with persantin (possibilities of evaluation of the results of therapy)].
    ROSINSKI J
    Munch Med Wochenschr; 1960 Sep; 102():1798-1800. PubMed ID: 13743533
    [No Abstract]   [Full Text] [Related]  

  • 31. DRUGS MADE IN GERMANY.
    BUCHER R
    Dis Chest; 1963 Dec; 51():187. PubMed ID: 14102115
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical experiences with the coronary drug SA30].
    WALTHER H
    Z Gesamte Inn Med; 1963 May; 18():394-8. PubMed ID: 13998721
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment with phenyl-propyl-diphenyl-propyl-amine (Segontin Hoechst) in coronary disease].
    DOBREANU-ENESCU V; TEODORINI S; HARNAGEA P
    Stud Cercet Med Interna; 1963; 4():243-53. PubMed ID: 14028230
    [No Abstract]   [Full Text] [Related]  

  • 34. [3-phenylpropyl-(2).]-1,1-diphenylpropyl-(3)-amine (lactate)].
    SCHMIDT HA; HAEUSSLER A; HOFFMANN W
    Arzneimittelforschung; 1963 Mar; 13():173-7. PubMed ID: 13991994
    [No Abstract]   [Full Text] [Related]  

  • 35. Recently introduced cardiovascular drugs under experimental test.
    KOHLER H
    Drugs Made Ger; 1963 Jun; 6():71-2. PubMed ID: 14034203
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical aspects of persantin, segontin and trimanyl in the light of the results of experimental studies on the coronary circulation in dogs].
    Janicki K; Wcislo W
    Pol Tyg Lek; 1967 May; 22(21):779-81. PubMed ID: 6040998
    [No Abstract]   [Full Text] [Related]  

  • 37. [The coronary dilatator effect of various reference drugs].
    Duchene-Marullaz P; Cosnier D; Grimald J
    Therapie; 1969; 24(4):617-20. PubMed ID: 5821999
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of Segontin, Persantin and nitroglycerin on the coronary artery. Experimental studies with cinecoronarography.
    DAHL M; KASANEN A; PELTONEN T
    Ann Med Exp Biol Fenn; 1962; 40():423-6. PubMed ID: 14024623
    [No Abstract]   [Full Text] [Related]  

  • 39. Dipyridamole, cerebrovascular disease, and the vasculature.
    Chakrabarti S; Freedman JE
    Vascul Pharmacol; 2008; 48(4-6):143-9. PubMed ID: 18342579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of caffeine and theophylline on coronary hyperemia induced by adenosine or dipyridamole.
    Salcedo J; Kern MJ
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):598-605. PubMed ID: 19496111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.